key: cord-0919383-6sk97gc4 authors: Evans, John P.; Zeng, Cong; Qu, Panke; Faraone, Julia; Zheng, Yi-Min; Carlin, Claire; Bednash, Joseph S.; Zhou, Tongqing; Lozanski, Gerard; Mallampalli, Rama; Saif, Linda J.; Oltz, Eugene M.; Mohler, Peter; Xu, Kai; Gumina, Richard J.; Liu, Shan-Lu title: Neutralization of SARS-CoV-2 Omicron Sub-lineages BA.1, BA.1.1, and BA.2 date: 2022-04-25 journal: Cell Host Microbe DOI: 10.1016/j.chom.2022.04.014 sha: 387be57c32276ec9b9fe1b0ea36ddb37a4fa640f doc_id: 919383 cord_uid: 6sk97gc4 Recent reports of SARS-CoV-2 Omicron variant sub-lineages, BA.1, BA.1.1, and BA.2, have reignited concern over potential escape from vaccine- and infection-induced immunity. We examine the sensitivity of these sub-lineages and other major variants to neutralizing antibodies from mRNA-vaccinated and boosted individuals, as well as recovered COVID-19 patients, including those infected with Omicron. We find that all Omicron sub-lineages, especially BA.1 and BA.1.1, exhibit substantial immune escape that is largely overcome by mRNA vaccine booster doses. While Omicron BA.1.1 escapes almost completely from neutralization by early-pandemic COVID-19 patient sera and to a lesser extent from sera of Delta infected patients, BA.1.1 is sensitive to Omicron-infected patient sera. Critically, all Omicron sub-lineages, including BA.2, are comparably neutralized by Omicron patient sera. These results highlight the importance of booster vaccine doses for protection against all Omicron variants, and provide insight into the immunity from natural infection against Omicron sub-lineages. 1 7 although boosted patients exhibited higher NT50 compared to the unvaccinated, albeit not 160 statistically significant (p > 0.05) (Fig. 2F) . We noted that the two-dose samples were collected 161 between 5-11 months after the second vaccination (median 9 months), and that boosted samples 162 were collected between 2-6 months (median 5 months) following the booster shot (Table 1) for comparison (see Fig. 1A ). For vaccine sera, we examined 10 randomly-selected HCW 177 samples with both post-two dose and post-booster dose samples (Table 1) . We observed 178 comparable resistance of these sub-lineages and the BA.1.1-ΔEPE mutant to neutralization from 179 both the two-dose vaccinated and boosted HCWs (Fig. 3A-B and Fig. S3) . Critically, and 180 consistent with the pattern of BA.1.1 shown in Fig. 1 , BA.1, BA.1.1-ΔEPE, as well as BA.2 all 181 exhibited reduced neutralization by the 2-dose mRNA vaccination sera, but showed an obviously 182 increased sensitivity to neutralization by the booster dose sera (p < 0.05) (Fig. 3A-B and Fig. S3) . the Omicron sub-lineages, and observed comparable levels of neutralization for all Omicron sub-187 lineages ( Fig. 3C and Fig. S3) . Again, the breadth of neutralization was heterogeneous across 188 the patients examined with some exhibiting strong neutralization of all variants ( Fig. 3D and Fig. 189 S3) (n = 7), strong neutralization of only Omicron sub-lineages ( Fig. 3E and Fig. S3 ) (n = 2), or 190 potent neutralization of ancestral D614G with weaker neutralization of Omicron sub-lineages ( Omicron sub-lineages were also seen regardless of vaccination status (Fig. 3H) While underlying mechanisms for this remain unclear, enhanced breadth of protection is likely 211 J o u r n a l P r e -p r o o f 9 due to additional affinity-maturation following a third antigen exposure 212 Muecksch et al., 2021) . Additionally, we were surprised to observe that the Delta variant exhibited 213 slightly greater resistance to post-booster vaccination samples than the Omicron variant (p < 0.05). 214 The reason underlying this difference is unclear, but may reflect a broadened nAb repertoire 215 following booster vaccination against all major variants of concern-however, the Omicron variant 216 may exhibit a conformation that is relatively sensitive to antibody-mediated neutralization due to • NT50 values and de-identified patient information will be deposited to the National Cancer 396 Institute SeroNet Coordinating Center. Additionally, NT50 values and de-identified patient 397 information reported in this paper will be shared by the lead contact upon request. 398 • This paper does not report original code. 399 • Any additional information required to reanalyze the data reported in this paper is available 400 from the lead contact upon request. Geometric mean NT 50 values in panels A and G are displayed at the top of plots along with the percentage of subjects with NT 50 values above the limit of detection; bars represent geometric mean +/-95% confidence interval, and for A and G significance is determined by one-way repeated measures ANOVA with Bonferroni's multiple testing correction while for B-F, significance was determined by two-tailed paired t-test. P-values are represented as *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant. U2 U3 U4 U5 U6 U7 U8 U9 U10 U11 U12 U13 U14 U15 V1 V2 V3 V4 V5 V6 V7 V8 B1 B2 B3 B4 B5 B6 B7 Hospitalized patient samples collected during the Omicron-wave are identified as "U" for unvaccinated, "V" for 2-dose vaccinated, and "B" for booster dose vaccinated. A longitudinal study of SARS-CoV-2-infected patients reveals a 537 high correlation between neutralizing antibodies and COVID-19 severity Vaccines elicit highly conserved cellular immunity 541 to SARS-CoV-2 Omicron A pan-sarbecovirus vaccine induces highly potent and durable neutralizing 544 antibody responses in non-human primates against SARS-CoV-2 Omicron variant Transmission of sars-cov-2 omicron 547 voc subvariants BA.1 and BA.2: Evidence from danish households Mutational and phylogenetic analyses of the two lineages 549 of the Omicron variant Quantitative 551 comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors Reduced pathogenicity of the SARS-CoV-555 2 omicron variant in hamsters SARS-CoV-2 B.1.617.2 Delta variant replication and immune 558 evasion Increased potency and breadth of SARS-CoV-2 561 neutralizing antibodies after a third mRNA vaccine dose Affinity maturation of SARS-564 CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations Neutralizing antibodies against the SARS-CoV-2 568 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster 569 vaccination Considerable escape of SARS-CoV-2 572 Omicron to antibody neutralization Spike mutation D614G alters SARS-CoV-2 fitness Increased risk of SARS-CoV-2 reinfection 578 associated with emergence of Omicron in South Africa Plasma neutralization of the SARS-CoV-2 583 Omicron variant Monitoring incidence of COVID-19 cases, 586 hospitalizations, and deaths, by vaccination status -13 U.S. jurisdictions Vaccine breakthrough infection with the SARS-590 CoV-2 Delta or Omicron (BA.1) variant leads to distinct profiles of neutralizing antibody responses SARS-CoV-2 593 variants of concern are emerging in India Occurrence and significance of Omicron BA. 1 596 infection followed by BA. 2 reinfection. medRxiv Developing pan-β-coronavirus vaccines against emerging 598 SARS-CoV-2 variants of concern 600 (2022a). Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants Sequence analysis of the emerging SARS-CoV-2 variant 603 Omicron in South Africa Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies Emergence and rapid 609 transmission of SARS-CoV-2 B.1.1.7 in the United States Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against 612 Omicron SARS-CoV-2 Cryo-EM structure of a SARS-CoV-2 Omicron spike protein 614 ectodomain Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody Receptor-binding domain-specific human neutralizing monoclonal antibodies against 620 SARS-CoV and SARS-CoV-2 Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. 623 The New England journal of medicine Structural and functional analysis of the 626 D614G SARS-CoV-2 spike protein variant Neutralization of SARS-CoV-2 variants of concern harboring 629 Q677H Neutralizing antibody against SARS-CoV-2 spike in 632 COVID-19 patients, health care workers, and convalescent plasma donors Impaired neutralizing antibody response 635 to COVID-19 mRNA vaccines in cancer patients The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron Evidence of escape of SARS-CoV-2 variant 641 B.1.351 from natural and vaccine-induced sera Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection Two-dose Vaccination (n=48) Booster-dose Vaccination (n=19) (Fig. 2F, Fig. 3H ). Comparisons between 480 two-groups were made using a paired two-tailed student's t-test with Welch's correction (Fig. S1 481 B-F). Comparisons between two "treatment" groups across multiple variants were made using a 482 two-way repeated measures ANOVA with Bonferroni post-test (Fig. 2D, Fig. S1A • Booster vaccination recovers Omicron immunity to levels comparable to Delta.• Sera from Omicron, but not D614G or Delta, COVID-19 patients neutralize Omicron.• The Omicron "EPE214" insertion does not dictate neutralization resistance. The emerging SARS-CoV-2 Omicron variants may threaten existing COVID-19 immunity. Evans and colleagues examine immunity against the BA.